Pulse Biosciences Posts $23.1M Q3 Loss, Cash Jumps to $189.2M on $95.8M ATM Raise
PLSE has more than doubled off its 52-week low of $12.56.
Summary
Pulse Biosciences ended Q3 with $189.2 million in cash after raising $95.8 million of net ATM proceeds, funding its atrial fibrillation pivotal program despite a widening $23.1 million quarterly loss.
Key Events · Earnings and Guidance · PLSE
-
Q3 Cash Climbs to $189.2M
Cash, cash equivalents and marketable securities totaled $189.2 million at September 30, 2026, up $87.6 million from $101.6 million at June 30, reflecting ATM proceeds.
-
$95.8M ATM Raise, Under 6% Dilution
The company raised $95.8 million of net proceeds through its ATM programs in Q3 and more than $150 million since May, representing less than 6% dilution, with approximately $64 million of capacity remaining.
-
Loss Widens on Clinical Spend
GAAP net loss was $23.1 million versus $19.4 million a year earlier, as total costs and expenses rose to $24.7 million from $20.5 million on clinical program and employee-related spend.
-
NANOPULSE-AF Fully Enrolled
The U.S. IDE pivotal study completed enrollment with 169 evaluable patients at 15 sites in under six months, three months ahead of plan; 12-month EU feasibility data on 100 patients is planned for Q1 2027.
Analysis · PLSE · Industrial Applications And Services
The balance sheet, not the income statement, is the quarter's headline. Pulse raised $95.8 million of net ATM proceeds in Q3 and more than $150 million since May while keeping dilution under 6%, lifting cash and marketable securities to $189.2 million from $101.6 million at June 30. That funds a multi-year runway through the NANOPULSE-AF pivotal readout and launch preparation, against roughly $15.3 million of quarterly operating cash burn. The cost side is moving the other way: GAAP expenses rose to $24.7 million from $20.5 million on clinical and headcount spend, and the net loss widened to $23.1 million from $19.4 million. Revenue remains nominal at $0.4 million from the controlled Vybrance launch. With about $64 million of ATM capacity left, further share issuance is likely, but the company is no longer funding a pivotal trial from a position of scarcity.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLSE was trading at $53.07 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $12.56 to $58.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.